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Objectives This study sought to evaluate in vivo the minimal dose of apolipoprotein (apo) A-IMilano phospholipid complex
(recombinant apoA-IMilano and 1-palmitoyl-2-oleoyl phosphatidylcholine complexes [ETC-216]) able to induce ath-
erosclerosis regression in a rabbit model of lipid-rich plaques.
Background A single high dose of recombinant apoA-IMilano has promoted atherosclerosis regression in animal models. More
recently, regression of atherosclerosis was achieved in coronary patients by repeated infusions of ETC-216.
Methods Thirty-six rabbits underwent perivascular injury at both carotid arteries, followed by a 1.5% cholesterol diet. After 90
days, rabbits were randomly divided into 6 groups and treated 5 times with vehicle or ETC-216 at 5, 10, 20, 40, or
150 mg/kg dose every 4 days. Carotid plaque changes were evaluated in vivo by intravascular ultrasound (IVUS) and
magnetic resonance imaging (MRI), performed before and at the end of treatments. Magnetic resonance imaging
scans were also recorded after administration of the second dose for rabbits infused with vehicle 40 or 150 mg/kg.
Results Atheroma volume in vehicle-treated rabbits increased dramatically between the first and the second IVUS analy-
ses (26.53%), whereas in ETC-216–treated animals, a reduced progression at the lower doses and a significant
regression at the higher doses, up to 6.83%, was detected. Results obtained by MRI analysis correlated signifi-
cantly with those at IVUS (r  0.706; p  0.0001). The MRI evaluations after the second infusion established
that a significant regression was achieved with only 2 administrations of the highest dose.
Conclusions These results confirm the efficacy of ETC-216 for atherosclerosis treatment and provide guidance for dose selec-
tion and frequency to obtain a significant reduction of plaque volume. (J Am Coll Cardiol 2008;51:1098–103)
© 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.12.010s
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vigh-density lipoprotein (HDL) cholesterol levels are a
otent inverse and independent epidemiologic risk factor for
ardiovascular diseases (1,2), and HDL or its major protein,
polipoprotein (apo) A-I, are well-established antiathero-
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ccepted December 2, 2008.clerotic agents in animal models (3,4). Several approaches
ave been attempted in recent years to increase HDL
holesterol levels, including the direct administration of
ynthetic HDL or apoA-I, as a whole or as a peptide
imetic (3–5).
See page 1110
Pre-clinical studies have previously shown that intravas-
ular infusions of synthetic HDL containing a genetic
ariant of apoA-I, apoA-IMilano, inhibit progression and
nduce rapid regression and remodeling of atherosclerosis
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ntravenous injections of synthetic HDL, constituted by re-
ombinant apoA-IMilano and 1-palmitoyl-2-oleoyl phosphati-
ylcholine complexes (ETC-216), induced atheroma regres-
ion in coronary patients. However, the 2 tested doses (15 and
5 mg/kg protein) induced about the same level of regression
n human coronary vessels, leaving open the question of the
inimal amount of ETC-216 required to achieve regression.
oreover, the optimal number of ETC-216 administrations
eeded to obtain a significant reduction in plaque size, an
mportant practical question in terms of any future clinical use,
as not addressed.
The primary objective of the current study was to estab-
ish the minimal effective dose of ETC-216 able to induce
therosclerosis regression in a rabbit model of lipid-rich soft
laques. The secondary objective was to determine the
owest number of administrations required to observe a
ignificant plaque regression. These goals were achieved by
n vivo assessment of plaque volume through intravascular
ltrasound (IVUS) and magnetic resonance imaging (MRI)
nalyses. In previous studies by our group, both techniques
ave been applied successfully to quantitative analysis of
rterial plaques in the same rabbit model (10,13,14).
ethods
xperimental protocol. Lipid-rich plaque formation was
nduced in male New Zealand White rabbits (Harlan, Italy)
s previously described (13). Procedures involving animals
nd their care were conducted in compliance with national
nd European Economic Community laws and policies.
At 90 days after surgery, pre-treatment right carotid
rtery scans were recorded by IVUS, followed by MRI scans
f both the right and left carotid arteries. Rabbits were then
andomized into 6 groups of 6 animals each and treated
ith vehicle (7.7% sucrose and 0.8% mannitol) or 5, 10, 20,
0, or 150 mg protein/kg body weight of ETC-216.
The ETC-216 was supplied by Esperion Therapeutics,
fizer Inc. (Plymouth, Michigan), prepared in 7.7% sucrose
nd 0.8% mannitol, at a concentration of 15 mg/ml protein.
he ETC-216 and vehicle were administered as an intra-
ugular infusion, at a constant rate of 1.0 ml/min every 4
ays, for a total of 5 doses. No signs of toxicity by treatment
ere observed at each dose administered.
Before administration of the third dose, rabbits infused
ith vehicle (control), 40 mg/kg ETC-216, and 150 mg/kg
TC-216 underwent MRI analysis at both carotid arteries.
ne week after infusion of the fifth (last) dose, all rabbits
nderwent a scan of both carotid arteries by MRI, followed
y an IVUS scan of the right carotid artery. Operators
esponsible for treatment administration were completely
linded with respect to the treatment.
VUS imaging. The IVUS evaluations of the right ca-
otid artery were performed using a mechanical IVUS
ystem (Galaxy 2, Boston Scientific, Fremont, California)
s described (13). Two blinded independent observerserformed the IVUS analyses.
he origin of the right carotid
rtery from the aortic arch was
sed as the anatomical landmark
o co-register pre- and post-
reatment scans. Atheroma area
as calculated as the external elas-
ic membrane area minus luminal
rea. Plaque area was measured on
ll slices covering the lesion. The
um of the areas was multiplied by
he slice thickness value (0.5 mm)
o obtain plaque volume. The
oint of maximal plaque formation
as considered the cross-section
ith the maximal plaque area.
Figure 1 Absolute Values and Percent
Changes Evaluated by IVUS
Absolute values (A) and percent change (B) of total atheroma volume evalu-
ated by IVUS at the right carotid arteries in rabbits treated with vehicle (control)
or different doses of ETC-216. Data are expressed as mean  SEM. (A) Open
bars represent pre-treatment; solid bars represent post-treatment. *p  0.05
versus control post-treatment. (B) §p  0.05 versus control; ¶p  0.0005 ver-
sus ETC-216 at 5 mg/kg; #p  0.05 versus ETC-216 at 10 mg/kg. ETC-216 
recombinant apolipoprotein A-IMilano and 1-palmitoyl-2-oleoyl phosphatidylcho-
line complexes; IVUS  intravascular ultrasound.
Abbreviations
and Acronyms
apo  apolipoprotein
ETC-216  recombinant
apolipoprotein A-IMilano and
1-palmitoyl-2-oleoyl
phosphatidylcholine
complexes
HDL  high-density
lipoprotein
IVUS  intravascular
ultrasound
MRI  magnetic resonance
imaging
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In Vivo Study of Plaque Changes by ApoA-IMilano March 18, 2008:1098–103RI. An MRI scan was performed in all animals on a 2-T
agnetic resonance (MR) imager (SMIS, Surrey, England)
ith a quadrature surface coil placed on the rabbit’s neck
sed as a receiver and a larger coil for transmitting (RAPID-
iomedical, Rimpar, Germany).
The MR images of both carotid arteries were acquired
efore and after administration of the paramagnetic contrast
gent B22956/1 (Bracco Imaging SpA, Turin, Italy) at a dose
f 0.075 mmol/kg (intravenously in the ear) to localize stenoses
nd to enhance the lesions. The MR angiography was obtained
ith a 3-dimensional gradient-echo (repetition time [TR]/
cho time [TE] 14/2 ms, flip 40°, voxel 312 312
33 m3). For arterial wall lesion imaging, axial T1-weighted
nd T2-weighted spin echocardiographic images were ac-
uired (TR/TE 1,800/40 ms for T2, TR/TE 600/15 ms
or T1, pixel  258 m, slice thickness  1.8 mm).
The MR images from different time points were co-
egistered by using the spinal cord structure as anatomical
eference and analyzed by 2 blinded observers. The MRI
laque area was measured on both carotid arteries and on all
lices covering the lesion. The sum of areas was multiplied
y the slice thickness value (1.8 mm) to obtain plaque
olume. For each carotid artery, plaque volumes were
alculated as the mean value from those obtained with the
ifferent contrast images (T2, T1 before contrast agent, T1
fter contrast agent).
tatistical analysis. Data are expressed as mean  SEM.
Pre
Figure 2 Examples of IVUS Images of Atherosclerotic Plaques
Before and After Treatment With Vehicle (Control) or
Plaque areas are identified in yellow. A progression is visible in the control anima
whereas a regression is observed in the ETC-216–treated rabbit. Abbreviations asroup differences were tested for statistical significance bynalysis of variance for repeated measurements with 1
rouping factor or 1-way analysis of variance, followed by
he Tukey post-hoc test; a value of p  0.05 was considered
tatistically significant. The Pearson correlation coefficient
as calculated for interobserver and intraobserver variability
Post
Control
ETC-216
(150 mg/Kg)
ired
mg/kg ETC-216
ure 1.
Figure 3 Percent Change in Plaque Area
at the Maximum Plaque Burden Evaluated by IVUS
Rabbits were treated with vehicle (control) or ETC-216. Data are expressed as
mean  SEM. §p  0.001 versus control; ¶p  0.005 versus ETC-216 at 5
mg/kg; #p  0.05 versus ETC-216 at 10 mg/kg. Abbreviations as in Figure 1.Acqu
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VUS, MRI, and histology.
esults
reatment effect evaluated by IVUS. In 5 of 36 animals,
he quality of IVUS images recorded at the end of treatment
id not allow reliable measurements of the plaque area;
herefore, the results described below refer to 31 rabbits. In
Figure 4 Absolute Values and Percent Changes Evaluated by M
Absolute values (A and C) and percent change (B and D) of total atheroma volum
of ETC-216. Data are expressed as mean  SEM. (A and C) Open bars represent
treatment; ^p  0.05 versus ETC-216 at 5 mg/kg. (B and D) §p  0.05 versus c
other abbreviations as in Figure 1.
Pre
Figure 5 Examples of T2-Weighted Magnetic Resonance Image
at the Same Level Before and After Treatments With
Plaque areas are identified in yellow. A marked progression is visible in the contro
whereas a regression is observed in the ETC-216-treated animal. Abbreviations asine with previous studies by our group (10,13), the inter-
bserver variability in plaque volume measurements was
.887 (p  0.0001) and the intraobserver variability was
.946 (p  0.001). Figure 1 shows absolute plaque volumes
nd percent variations that occurred during the treatment
eriod, and examples are shown in Figure 2. Pre-treatment
laque volumes were not different among the 6 groups (Fig.
A). Total atheroma volume in the vehicle (control) group
uated by MRI in rabbits treated five times with vehicle (control) or different doses
atment; solid bars represent post-treatment. *p  0.05 versus control post-
¶p  0.05 versus ETC-216 at 5 mg/kg. MRI  magnetic resonance imaging;
Post
Control
ETC-216
(150 mg/Kg)
Carotid Arteries Acquired
le (Control) or 150 mg/kg of ETC-216
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In Vivo Study of Plaque Changes by ApoA-IMilano March 18, 2008:1098–103ncreased dramatically in the time between the first and the
econd IVUS evaluation (Fig. 1). In contrast, ETC-216 at
he 5- and 10-mg/kg doses reduced atheroma progression.
t the 3 highest doses, a progressive and significant regres-
ion of plaque volume was observed, ranging from 1.5 
.17% with 20 mg/kg to 6.83  2.86% with 150 mg/kg
dministration.
Percent changes by treatments were also evaluated at the
aximum plaque burden. A similar, marked plaque regres-
ion was observed with the administration of the 3 highest
oses of ETC-216 (Fig. 3).
reatment effect evaluated by MRI. In some animals,
R images were not analyzable because of intense breath-
ng or chewing movements; therefore, results refer to 22
nimals for the left carotid artery and 27 rabbits for the right
arotid artery. In line with previous results by our group
14), the interobserver variability in plaque volume measure-
ents was 0.776 (p  0.0001) and the intraobserver
ariability was 0.933 (p  0.0005). Absolute plaque volume
nd percent variations were evaluated in the 6 groups before
nd at the end of treatments; results are shown in Figure 4.
nalyses of right and left carotid arteries showed a similar
rend and were consistent with the results obtained by
VUS. Pre-treatment plaque volumes again did not differ
mong groups (Figs. 4A and 4C). Total atheroma volume in
ontrols strongly increased during the treatment period
Figs. 4 and 5). Although not significant, the 10-mg/kg
TC-216 treatment resulted in a reduced progression of
laque volume. Significantly reduced progression (right
arotid artery) or regression (left carotid artery) were de-
ected at the 20-mg/kg dose, whereas a clear and compara-
le regression was measured at 40 and 150 mg/kg ETC-216
7.29  1.79% and 6.56  2.68% at the right carotid
rtery and 6.04  2.10% and 6.76  4.41% at the left
arotid artery, respectively) (Figs. 4 and 5).
Changes of plaque volume after 2 administrations were
valuated by MRI to determine timing of treatment
fficacy. Results were similar for the right and left carotid
rteries (Fig. 6). In the control group, a progressive
ncrease in plaque volume was detected. At the 40-mg/kg
ose, a small, nonsignificant plaque regression was seen
fter 2 administrations, whereas just 2 infusions of 150
g/kg ETC-216 were associated with significant plaque
egression.
omparison between IVUS and MRI measurements. A
orrelation between IVUS and MRI plaque volume changes
y treatment was assessed at the right carotid artery (Fig. 7).
highly significant linear regression was obtained (r 
.706; p  0.0001).
iscussion
he major finding of this study is that multiple intravenous
dministrations of 5 different doses of ETC-216 in a rabbit
odel of carotid soft lipid-rich plaque resulted in a dose-elated effect on plaque volume, ranging from a lower progres- cion to a marked regression. As in previous studies (8–10),
poA-IMilano administrations affected plaque size mainly by
owering plaque lipid accumulation (data not shown).
Intravascular ultrasound and MRI have emerged as the
referred imaging modalities to evaluate the impact of
harmacological therapies on arterial plaque progression/
egression (10,12,15,16). Both IVUS and MRI have been
pplied by our research group to characterize the same
abbit model used in the present study (13,14) and to
nvestigate the efficacy of acute administrations of synthetic
DL containing apoA-IMilano in promoting plaque regres-
ion (10). As expected on the basis of previous findings (14),
ata obtained in this study by the 2 methods were compa-
able and significantly correlated, and were highly correlated
ith histology (IVUS vs. histology: r  0.845, p  0.001;
RI vs. histology: r  0.775, p  0.005).
The present study was designed to identify the minimal
ffective dose of ETC-216 capable to determine a signifi-
Figure 6 Percent Change of Total Atheroma
Volume at MRI After 2 and 5 Administrations
Percent change of total atheroma volume at right (A) and left (B) carotid arter-
ies evaluated by MRI after 2 and 5 administrations of vehicle or ETC-216 (40
mg/kg and 150 mg/kg). Shaded bars represent effects of 2 administrations;
solid bars represent effects of 5 administrations. Data are expressed as
mean  SEM. ¶p  0.05 versus control after 2 administrations; §p  0.05
versus control after 5 administrations. Abbreviations as in Figures 1 and 4.ant plaque regression, with the same treatment strategy as
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March 18, 2008:1098–103 In Vivo Study of Plaque Changes by ApoA-IMilanopplied to coronary patients (12). The 2 highest doses given
o rabbits (40 and 150 mg/kg) correspond to the doses
dministered to patients (15 and 45 mg/kg), keeping in
ccount pharmacokinetic differences between rabbits and
umans (17). To identify a possible minimal effective dose, 3
ower doses of ETC-216 were also included in the present
tudy. The results obtained by IVUS and MRI were compa-
able, with no differences being observed in the response of left
nd right carotid arteries except for the dose of 20 mg/kg,
hich was associated with regression (Figs. 1 and 4) or
educed progression (Fig. 4), altogether indicating stabili-
ation of plaque volume. Interestingly, the 2 highest doses
40 and 150 mg/kg) were associated with regression of
laque size, with no greater regression occurring at the
igher dose, similar to results obtained in the clinical study
12). From these results it can be concluded that, in this
nimal model, the minimal dose of ETC-216 required to
btain a plaque regression with 5 treatments is between 20
nd 40 mg/kg. It could be speculated that for humans this
alue may correspond to 8 to 15 mg/kg (17).
Another goal of the study was to evaluate the possibility
hat a significant regression of plaque volume could be
chieved after just 2 administrations of the 2 highest doses.
lthough no significant effects were determined by 2
nfusions of the 40-mg/kg dose, a significant regression was
bserved after 2 administrations of 150 mg/kg ETC-216.
hese results are in line with a very recent study showing a
ignificant plaque regression after 2 administrations of 75
g/kg ETC-216 (18).
In conclusion, the present results indicate the remarkable
fficacy of 5 administrations of ETC-216 in reducing
rogression or inducing regression of atheroma, and suggest
he feasibility of reducing the number of administrations to
Figure 7 Correlation Between IVUS and MRI Plaque
Volume Percent Change at the RCAs
Solid triangles  control; open circles  5 mg/kg ETC-216; solid diamonds 
10 mg/kg ETC-216; open squares  20 mg/kg ETC-216; solid circles  40
mg/kg ETC-216; open triangles  150 mg/kg ETC-216 (r  0.706; p 
0.0001). RCA  right carotid artery; other abbreviations as in Figures 1 and 4.chieve a significant plaque regression in humans. In addi-ion, the excellent correlation between IVUS and MRI data
ndicates the possibility of a future wide range application of
his noninvasive methodology to the monitoring of the
fficacy of pharmacological treatments.
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